OMEICOS Therapeutics
PrivateLast Round
Grant
Jun 21, 2023
Total Funding Raised
$42.26M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
OMEICOS Therapeutics operates in Healthcare & Life Sciences and is based in Berlin. Its latest recorded funding round was a Grant round in June 2023.
OMEICOS Therapeutics is a biopharmaceutical company that develops first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular, ophthalmic, and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OMEICOS Therapeutics Comparables
Compare OMEICOS Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Khondrion | 86% | |
| Pharming Group N.V. | 80% | |
| OnKure Therapeutics | 78% |
For institutional investors. Book with your work email.
OMEICOS Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 21, 2023 | ||||
| Series C | Nov 2, 2018 | ||||
| Series B Extension | Oct 4, 2017 | ||||
| Grant | Jun 7, 2017 | ||||
| Series B | Mar 1, 2017 | ||||
Series A | Apr 15, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
OMEICOS Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Ministry of Education and Research | Grant |
| Forbion | Series C |
| IBB Ventures | Series B Extension, Series B, Series A, Seed, Series C |
| Bundesministerium für Bildung und Forschung | Grant |
| Remiges Ventures | Series B, Series C, Series B Extension |
| Ascenion | Series B, Grant |
| Vesalius Biocapital Partners | Series B Extension, Series C, Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors increased 234% MoM.
- Feb 25, 2026
Grew 80% QoQ from 5 to 9 employees.
For institutional investors. Book with your work email.
OMEICOS Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about OMEICOS Therapeutics's valuation, stock price, and market status.
Is OMEICOS Therapeutics a public or private company?
OMEICOS Therapeutics is a private company.
What is the current stock price of OMEICOS Therapeutics?
OMEICOS Therapeutics is a private company, so its shares have no public market price. Caplight tracks OMEICOS Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is OMEICOS Therapeutics worth (valuation)?
Valuation information for OMEICOS Therapeutics is not publicly available.
Can I buy OMEICOS Therapeutics stock?
OMEICOS Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was OMEICOS Therapeutics's last funding round?
OMEICOS Therapeutics's most recent funding round was Grant on June 21, 2023.
Who are the main investors in OMEICOS Therapeutics?
Key investors in OMEICOS Therapeutics include Forbion, Remiges Ventures, Vesalius Biocapital Partners.
Will OMEICOS Therapeutics IPO soon?
No public IPO plans have been announced for OMEICOS Therapeutics.
How can I track OMEICOS Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in OMEICOS Therapeutics's shares on secondary markets.